Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Parents abused by their children often suffer in silence – specialist therapy is helping them find a voice 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Locked up then locked out: how NZ’s bank rules make life for ex-prisoners even harder 
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination 
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength 
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
Why have so few atrocities ever been recognised as genocide? 
Debate over H-1B visas shines spotlight on US tech worker shortages 
6 simple questions to tell if a ‘finfluencer’ is more flash than cash 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Coca-Cola Japan and Kirin Holdings will develop health drinks that contain the live bacteria, lactococcus lactis strain plasma (LC-Plasma), an ingredient patented by Kirin that is used in the company's health drinks.
Kirin claims that the live bacteria boosts immunity in healthy people.
Kirin is the first among companies that make foods and beverages they claim to boost immunity to have been approved by Japan's Consumer Affairs Agency in 2020 to advertise its products as such.
Coca-Cola Japan plans to put LC-Plasma into three of its brands, Georgia, Irohasu, and Minute Maid.
The Consumer Affairs Agency has also given the go-ahead for the drinks to be advertised as having the advantage.
The partnership demonstrates Coca-Cola Japan's intention to improve its position in the health beverage market. According to market research firm Inryo Soken, Coca-Cola has a 26 percent market share in soft drinks but has not advanced significantly in the market for health beverages.
On the other hand, Kirin is increasing sales of its LC-Plasma component and sees health products as its next area of growth. It anticipates that by 2027, sales of health drinks will have increased fivefold from their current level to 50 billion yen.
Taisho Pharmaceutical Holdings, as well as candy manufacturers including Morinaga & Co. and Kanro, have already purchased the component from Kirin.
Although supplying a rival with distinctive ingredients would negate Kirin's advantage, collaborating with Coca-Cola might let it expand its market.
